Cellectar Biosciences, Inc. (NASDAQ:CLRB) [Trend Analysis] regains street interests, as shares ascend 228.57% on Monday and it traded at $3.45. Cellectar Biosciences, Inc. (CLRB) released that its previously filed non-provisional US and International (PCT) patent applications for Phospholipid-Ether Analogs as Cancer Targeting Drug Vehicles have received their US Patent and Trademark Office (USPTO) identification numbers and have been published by the USPTO, which marks the next step in the application process for approval and issuance of these patents.
As previously stated, these patents will protect both composition of matter and method of use for those phospholipid drug conjugates, or PDCs, developed with Cellectar’s proprietary phospholipid-ether delivery vehicle conjugated with any existing or future cytotoxic agents, including chemotherapeutics such as paclitaxel, for targeted delivery to cancer cells and cancer stem cells.
Moving toward technical analysis, the current ratio, or the liquidity ratio of a company was calculated 0.80 as compared to its debt to equity ratio stands at 0.08. This is an important indicator as a higher ratio typically suggests that investors are investing more confidently as compared to companies in the same industry has lower ratios. When calculating in the EPS estimates for the current year from sell-side analysts, the Price to current year EPS stands at 59.90%.
Major bullish and bearish trends reflect in rating research, from pool of WSJ analyst gave as a highest price target, medium point hits to , while the lowest share price targets assigned . The data compelled by Wall Street Journal average suggest average price target would by , where as current price stood at .
Moderately analysts issue miscellaneous recommendation for CLRB, as experts rated as “BUY” security, analyst have faith on stocks as “Overweight,” moreover experts rated as “Hold”.
As for as concerns shares volumes, in share capital Cellectar Biosciences, Inc. (NASDAQ:CLRB) has 1.16 million outstanding shares. The firm’s institutional ownership remained 6.70% while insider ownership included 4.60%.
The stock showed weekly upbeat performance of 150.00%, which maintained for the month at 82.54%. Likewise the positive performance for the quarter recorded as -29.59% and for the year was -87.27%, while the YTD performance remained at -53.38%.